NCT02004886View on ClinicalTrials.gov

A Study to Assess the Safety, Tolerability and Glucose-Lowering Efficacy of MK-0893 in Participants With Type 2 Diabetes Mellitus (MK-0893-005)

PHASE2CompletedINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

August 11, 2006

Primary Completion Date

February 7, 2007

Study Completion Date

February 7, 2007

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

MK-0893

10 mg and 100 mg tablets

DRUG

Metformin

500 mg metformin tablets

DRUG

Placebo

Placebo tablets matching MK-0893

DRUG

Placebo

Placebo tablets matching metformin

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT02004886 - A Study to Assess the Safety, Tolerability and Glucose-Lowering Efficacy of MK-0893 in Participants With Type 2 Diabetes Mellitus (MK-0893-005) | Biotech Hunter | Biotech Hunter